The 2025 American Heart Association (AHA) annual conference wrapped up on November 10 in New Orleans, Louisiana. The four-day event was filled with educational presentations, networking opportunities, and an unparalleled look into the research conducted by worldwide leaders in cardiovascular care. This year's AHA Scientific Sessions was the first time the event grew into a four-day event, up from the previous three-day events in previous years.
Today, we're taking a few moments to highlight a sampling of the abstracts presented at the 2025 AHA annual meeting. The following abstracts are focused on or related to lipid disorders. For a complete look at all the abstracts presented at the 2025 AHA Scientific Sessions, visit the event's official website.
- Description: The lipid-lowering efficacy and safety profile of oral PCSK9 inhibitors have not yet been systematically evaluated, despite being a promising alternative to injectable PCSK9 inhibitors.
- Conclusion: Oral PCSK9 inhibitors significantly reduced LDL-C, lipoprotein(a), apolipoprotein B, and total cholesterol compared to placebo, with no significant reduction in triglycerides. Among the agents studied, MK-0616 demonstrated the greatest overall LDL-C lowering effect.
- Description: Researchers presented the case of a 34-year-old male with compound heterozygous FH (HeFH) with peak LDL >600mg/dl and premature ASCVD; anterior STEMI at age 25 requiring PCI to LAD complicated by VF arrest, and NSTEMI s/p PCI to LAD at 32. Alirocumab was replaced by Inclisiran, but then ultimately reverted. Evinacumab was then added. In this patient, Evinacumab, an angiopoietin-like-protein 3 (ANGPTL3) inhibitor, was effective to achieve the LDL target.
- Conclusion: This case highlights the importance of recognizing limitations in existing lipid-lowering strategies and the need for personalized treatment.
- Description: This study evaluated the impact of escalating lipid-lowering strategies on coronary artery calcium progression and lipid parameters.
- Conclusion: Escalating lipid-lowering therapy, notably with the addition of PCSK9 inhibition, was associated with a significant attenuation of coronary artery calcium progression and improvement in lipid biomarkers, supporting the use of intensive lipid-lowering strategies to mitigate atherosclerotic progression.
- Description: The study investigated the impact of diabetes mellitus on cardiovascular outcomes among patients with elevated lipoprotein(a).
- Conclusion: Researchers noted the presence of diabetes mellitus in patients with elevated lipoprotein(a) levels was notably associated with an increased risk of major adverse cardiovascular events, atherosclerotic cardiovascular disease, new-onset heart failure, cardiac-related hemodynamic instability, all-cause hospitalizations, and all-cause mortality. There was no notable difference between the presence of diabetes mellitus and new-onset aortic valve stenosis and new-onset atrial fibrillation.
- Description: Researchers noted that the 2018 AHA/ACC cholesterol guideline classifies a subgroup of individuals with established atherosclerotic cardiovascular disease (ASCVD) as being at “very high risk” for recurrent ASCVD to guide lipid-lowering therapy, and sought to compare the 2018 guideline to a newly developed prediction model.
- Conclusion: The newly developed prediction model was able to more accurately estimate 10-year recurrent ASCVD risk in two large contemporary United States adult population cohorts.
Sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2025 Guideline Central, all rights reserved.